BPC-157 (5 mg Vial) Dosage Protocol

BPC-157 (5 mg Vial) Dosage Protocol

#dosing-schedule .dr-container > header { margin-bottom: 0 !important; padding-bottom: 0 !important; }
#dosing-schedule .dr-container > header * { margin-bottom: 0 !important; }
#dosing-schedule .dr-container > header::before, #dosing-schedule .dr-container > header::after { content: none !important; display: none !important; }
#dosing-schedule .dr-container > section:first-of-type { margin-top: 0 !important; display: flow-root; }
#dosing-schedule .dr-container > section:first-of-type h2:first-child { margin-top: 0 !important; }
#dosing-schedule .dr-container .wp-block-spacer, #dosing-schedule .dr-container hr { display: none !important; height: 0 !important; margin: 0 !important; border: 0 !important; }

Quickstart Highlights

BPC-157 (Body Protection Compound-157) is a 15-amino acid synthetic peptide derived from human gastric juice proteins that accelerates localised tissue repair via FAK-paxillin pathway activation, VEGF upregulation, and NO-pathway normalisation.[1] It is widely used for musculoskeletal injury recovery and gut mucosal protection.

  • Reconstitute: Add 2.0 mL bacteriostatic water → 2.5 mg/mL concentration.
  • Standard dose: 250–500 mcg once or twice daily (subcutaneous).
  • Easy measuring: At 2.5 mg/mL on a U-100 syringe, 1 unit = 0.01 mL = 25 mcg. A 250 mcg dose = 10 units / 0.10 mL.
  • Storage: Lyophilised: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C; use within 4 weeks.
BPC-157 5mg Vial

Dosing & Reconstitution Guide

Educational protocol for localised and systemic subcutaneous BPC-157 administration

Standard Daily Protocol (2.0 mL = 2.5 mg/mL)

Dose Units (U-100) Volume Frequency Vial Duration
250 mcg (low) 10 units 0.10 mL Once or twice daily 20 injections (10 days at 2×/day)
500 mcg (standard) 20 units 0.20 mL Once or twice daily 10 injections (5 days at 2×/day)

Begin at the 250 mcg once-daily dose for the first 3–5 days to assess local tolerance, then advance to 500 mcg once or twice daily as appropriate. For acute musculoskeletal injuries, injecting subcutaneously near (but not into) the injury site can enhance local FAK-paxillin activity. For gut-related applications, the injection site is less important as BPC-157 distributes systemically.

Reconstitution Steps

  1. Allow frozen lyophilised vial to reach room temperature (10–15 minutes).
  2. Draw 2.0 mL bacteriostatic water with a sterile syringe.
  3. Inject slowly down the inner vial wall to avoid foaming.
  4. Gently swirl until fully dissolved — do not shake. Solution should be clear and colourless.
  5. Label with reconstitution date; refrigerate at 2–8 °C, protected from light. Use within 4 weeks.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on a 4-week cycle at 500 mcg once daily (28 injections, 14 mg total).

  • BPC-157 Vials (5 mg each): 14 mg needed ÷ 5 mg per vial → 3 vials.
  • Insulin Syringes (U-100, 0.3 mL / 30-unit): 28 injections → 28 syringes.
  • Bacteriostatic Water (10 mL bottles): 2.0 mL per vial → 1 × 10 mL bottle per 5 vials.
  • Alcohol Swabs: 2 per injection → 56 swabs per 4-week cycle.
BPC-157 5mg
View Supplier
Insulin Syringes
View Supplier
Bacteriostatic Water
View Supplier
Alcohol Pads
View Supplier

Protocol Overview

  • Goal: Accelerate localised tissue repair via FAK-paxillin pathway, VEGF upregulation, NO-pathway normalisation, and gut mucosal protection.[1]
  • Schedule: Daily subcutaneous injection for a 4-week cycle; 2-week rest before reassessment.
  • Dose range: 250–500 mcg once or twice daily.
  • Reconstitution: 2.0 mL BAC water per 5 mg vial → 2.5 mg/mL.
  • Injection site: Near injury site (subcutaneous) for musculoskeletal; abdomen for gut applications.

Dosing Protocol

  • Starting dose: 250 mcg (10 units / 0.10 mL) once daily for Days 1–5.[1]
  • Standard dose: 500 mcg (20 units / 0.20 mL) once or twice daily from Day 6+.
  • Cycle: 4 weeks on, 2 weeks off; reassess and repeat if needed.
  • For acute injuries: Inject subcutaneously within 2–5 cm of the injured tissue when safely accessible.

Storage Instructions

  • Lyophilised: Store at −20 °C (−4 °F); protect from moisture and light.
  • Reconstituted: Refrigerate at 2–8 °C. Do not freeze. Use within 4 weeks.
  • Appearance: Clear, colourless solution. Discard if cloudy, coloured, or particulate.

Important Notes

  • For acute injuries, injecting near the injury site (not into muscle or joint) maximises BPC-157’s local FAK-paxillin and VEGF effects.
  • WADA-prohibited (Category S2) — competitive athletes subject to anti-doping rules must not use BPC-157.
  • BPC-157 is often combined with TB-500 for complementary local + systemic repair. See the Wolverine Stack Protocol.
  • Rotate injection sites daily; record site and dose to track local reactions.

How This Works

BPC-157 is a 15-amino acid synthetic peptide (GEPPPGKPADDAGLV) derived from gastric juice proteins. Its primary repair mechanism involves activation of the FAK-paxillin pathway in tendon fibroblasts, fibroblasts, and endothelial cells, driving cell outgrowth and migration into injured tissue.[1]

Concurrently, BPC-157 upregulates VEGF receptor expression to stimulate new blood vessel formation, and normalises the nitric oxide (NO) pathway to restore vascular function at the injury site. It reduces prostaglandin E2 production, blunting inflammatory pain and swelling during the early repair phase. In the gut, it protects the mucosal lining, promotes epithelial repair, and counteracts NSAID- and corticosteroid-induced damage — which is why it has been studied in models of inflammatory bowel disease and leaky gut.[1]

Potential Benefits & Considerations

  • Tendon and muscle repair: Extensive preclinical evidence across 35 studies; benefit in tendon, muscle, bone, and cartilage repair.[1]
  • Gut protection: Reduces NSAID-induced gut damage; promotes mucosal healing in colitis models.
  • Safety profile: No significant adverse effects in preclinical studies at standard research doses; human safety data limited to case reports and one small pilot study.
  • WADA status: Prohibited in- and out-of-competition (S2: Non-Approved Peptide Hormones).
  • Synergy with TB-500: Best combined as the Wolverine Stack for comprehensive local + systemic tissue repair. See What Is the Wolverine Stack?

Lifestyle Factors

  • Maintain adequate dietary protein (1.2–1.6 g/kg) to provide amino acids for collagen and tissue synthesis.
  • Avoid NSAIDs during a BPC-157 protocol — they can blunt the NO-pathway and VEGF signalling that BPC-157 potentiates.
  • Gentle mobilisation (range-of-motion exercises) within pain-free range supports capillary ingrowth and fibroblast recruitment.
  • Adequate sleep (7–9 hours) supports anabolic repair processes.

Injection Technique

  • Clean vial stopper and injection site with separate alcohol swabs; allow both to air-dry fully.
  • Using a 29–31 gauge insulin syringe (5/16″ to 1/2″ needle), draw the calculated dose.
  • Pinch a skin fold; insert needle at 45° into subcutaneous tissue (90° acceptable with short needles into a pinched fold)[CDC].
  • Inject slowly over 2–3 seconds; do not aspirate. Withdraw and apply gentle pressure.
  • Rotate sites (abdomen, thighs, upper arms); dispose of syringe in sharps container immediately.

Important Note

This content is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. This peptide is not approved for human therapeutic use. For research use only.

References


  • Gwyer D et al. — PMC (2025) — Orthopaedic Review of BPC-157
    — Comprehensive review of 35 preclinical studies and 1 human pilot trial covering tendon, muscle, bone, and cartilage repair; FAK-paxillin mechanism
    View Source

  • Sikiric P et al. — Journal of Physiology and Pharmacology (multiple)
    — BPC-157 FAK-paxillin pathway activation in tendon fibroblasts; NO-pathway and VEGF upregulation mechanisms
    View Source

  • Bachem Peptide Technical Guide
    — Handling and Storage Guidelines for Peptides (lyophilised and reconstituted forms)
    View Source

  • CDC — General Best Practice Guidelines for Immunization
    — Subcutaneous injection technique, angle, and site rotation guidance
    View Source